print

Investor Relations

Stock price graph
     
CRIS [NASDAQ]
$4.67  - 0.17 down   (3.512%)
Day Range:
4.67 - 4.87
52-week Range:
2.70 - 5.65
Volume:
406,500
4:00 PM ET on May 17, 2012
Delayed at least 20 minutes. Provided by eSignal.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.

View all »   RSSRecent Releases

May 17, 2012
Curis Announces Collaborators' Presentation of Erivedge(TM) and Debio 0932 Clinical Data at ASCO Annual Meeting

May 8, 2012
Curis Reports First Quarter 2012 Financial Results

Contact IR

Curis, Inc.
4 Maguire Road
Lexington, MA 02421
Phone: 617-503-6500
E-mail: info@curis.com

Transfer Agent

Computershare Shareowner Services
480 Washington Boulevard
Jersey City, New Jersey 07310
Phone (US): 877-810-2248 / (Ex-US) 201-680-6578
Website: www.bnymellon.com/shareowner/equityaccess

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.


© Curis Inc. 2012 - All Rights Reserved